Publikation
A T-cell antigen atlas for meningioma: novel options for immunotherapy.
Wissenschaftlicher Artikel/Review - 27.06.2023
Medici Gioele, Freudenmann Lena Katharina, Velz Julia, Wang Sophie Shih-Yüng, Kapolou Konstantina, Paramasivam Nagarajan, Mühlenbruch Lena, Kowalewski Daniel Johannes, Vasella Flavio, Bilich Tatjana, Frey Beat M, Dubbelaar MariLisa, Patterson Angelica Brooke, Zeitlberger Anna Maria, Silginer Manuela, Roth Patrick, Weiss Tobias, Wirsching Hans-Georg, Krayenbühl Niklaus, Bozinov Oliver, Regli Luca, Rammensee Hans-Georg, Rushing Elisabeth Jane, Sahm Felix, Walz Juliane Sarah, Weller Michael, Neidert Marian Christoph
Bereiche
PubMed
DOI
Kontakt
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Seiten
Kurzbeschreibung/Zielsetzung
Meningiomas are the most common primary intracranial tumors. Although most symptomatic cases can be managed by surgery and/or radiotherapy, a relevant number of patients experience an unfavorable clinical course and additional treatment options are needed. As meningiomas are often perfused by dural branches of the external carotid artery, which is located outside the blood-brain barrier, they might be an accessible target for immunotherapy. However, the landscape of naturally presented tumor antigens in meningioma is unknown. We here provide a T-cell antigen atlas for meningioma by in-depth profiling of the naturally presented immunopeptidome using LC-MS/MS. Candidate target antigens were selected based on a comparative approach using an extensive immunopeptidome data set of normal tissues. Meningioma-exclusive antigens for HLA class I and II are described here for the first time. Top-ranking targets were further functionally characterized by showing their immunogenicity through in vitro T-cell priming assays. Thus, we provide an atlas of meningioma T-cell antigens which will be publicly available for further research. In addition, we have identified novel actionable targets that warrant further investigation as an immunotherapy option for meningioma.